Clinical Trials Logo

Reduction Mammoplasty clinical trials

View clinical trials related to Reduction Mammoplasty.

Filter by:
  • None
  • Page 1

NCT ID: NCT04785638 Completed - Pain, Postoperative Clinical Trials

An Open-label Safety and Pharmacokinetic Study of INL-001 in Adults Following Various Open Soft-Tissue Surgeries

Start date: April 14, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter, Phase 3, open-label, safety, tolerability, and characterization of pharmacokinetics study of the INL 001 (bupivacaine HCl) implant, at 300 mg, in patients following various soft-tissue surgeries: open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty.

NCT ID: NCT03280043 Completed - Hemorrhage Clinical Trials

Risk of Hematoma After Ketorolac Use in Reduction Mammoplasty.

Start date: September 1, 2015
Phase: N/A
Study type: Observational

The investigators hope to answer the question, "does ketorolac increase the risk of hematoma after reduction mammoplasty?" using a case-control study. All patients who developed a hematoma post reduction mammoplasty (cases) at our institution, and match these with women who had an uncomplicated reduction mammoplasty (controls), and then compare frequency of ketorolac exposure between these two groups as the primary outcome. If ketorolac increases the risk of hematoma, one should expect cases to have been exposed to ketorolac more frequently than controls. Based on previously existing literature, the investigators hypothesize that cases and controls will not differ in their ketorolac exposure, that is, ketorolac does not increase the risk of hematoma.